Bank of America increased Gilead’s price target to $154 from $144 and maintains a Buy rating. The firm values the company’s HIV franchise growth and anticipates gains from recent and upcoming launches. Stay informed with hedge fund-level data and powerful investing tools for smarter decisions. Access the latest news and analysis to maximize your portfolio’s potential. Gilead voluntarily recalls one lot of Veklury for Injection 100 mg/vial. BKNG, GILD, ADI show strong buy signals on technical charts. Citi raises Gilead’s price target to $140 from $135. UBS upgrades Gilead to Buy from Neutral. Gilead Sciences receives a Buy rating and a 2027 re-rating target due to PrEP-led growth and pipeline upside.

Read more at Yahoo Finance: Gilead price target raised to $154 from $144 at BofA